Novo Nordisk Reduces Ozempic Price to Compete With Indian Generics

Novo Nordisk is set to cut the Ozempic price in India as Indian generics flood the market following the patent expiry.

The Danish company aims to stay competitive against low-cost semaglutide injections launched by local pharma players. With generics priced significantly lower, Novo Nordisk’s move ensures patients still have access to its branded Ozempic while the company protects its market share in India’s growing diabetes and obesity treatment sector.

The move marks a major shift for Novo Nordisk’s Ozempic pricing strategy in one of the world’s fastest-growing diabetes and obesity treatment markets. Indian pharmaceutical companies including Sun Pharma, Dr. Reddy’s and Zydus have launched their own generic semaglutide injections within days of the patent lapse. Those generics are priced at a fraction of the branded drug, pushing Novo to cut its list price by roughly 30–50 percent to stay competitive.

Also Read: How Semaglutide Works: The Breakthrough Weight-Loss Drug

Ozempic, which currently sells for about Rs 8,800 to Rs 11,175 per month in India, may be reduced to around Rs 5,000-Rs 6,000 under the new pricing plan. Even after the discount, this price will still sit above many generic rivals. The company aims to protect its market share and doctor loyalty as customers and healthcare providers shift attention to more affordable semaglutide options.

Generics now available are significantly cheaper, with some priced under Rs 5,000 per month and headline discount levels as steep as 70-90 percent compared with branded equivalents. This puts pressure on Novo Nordisk’s traditional premium pricing model for Ozempic, which helped establish its foothold in diabetes and weight-loss therapy but now faces disruption across India’s price-sensitive healthcare landscape.